Over the past several years, with the recognition of tumor immune escape, several immune checkpoint molecules have been identified for cancer immunotherapy, such as PD-1: PD-L1 and CTLA-4: CD80/CD86 (1–3). This evidence concerns the gene CD274 and cancer.